<p>Association of <em>MDM4</em> Gene rs4245739 Polymorphism with the Risk and Clinical Characteristics of Colorectal Cancer in a Chinese Han Population</p>

Abstract

Background: Studies show that MDM4 may play a pivotal role in colorectal cancer (CRC). Recently, a host of studies suggest that MDM4 gene rs4245739 polymorphism may modify the risk of different cancers. Methods: In this study, we were interested whether MDM4 gene rs4245739 polymorphism correlated with the risk and clinical characteristics of CRC. Logistic regression was adopted to estimate the association of rs4245739 polymorphism and CRC risk. Results: We enrolled 444 CRC patients and 530 controls and found MDM4 gene rs4245739 polymorphism may decrease the risk of CRC. Stratified analyses uncovered that this variant was connected to a less risk of CRC in females, non-drinkers, non-smokers, and people under 60 years old. Additionally, rs4245739 polymorphism was related to TNM staging, pathological type, tumor size, and location of CRC. Furthermore, this polymorphism was significantly linked with the survival of CRC. Conclusion: Totally, this study suggests that MDM4 rs4245739 polymorphism is linked with the risk and clinical characteristics of CRC.

Five MDM4 gene polymorphisms on cancer risk: An updated systematic review and meta-analysis

“…For polymorphisms of MDM4 gene (rs1380576, rs1563828, rs10900598, rs11801299, and rs4245739), a total of 15 articles (including 29 case–control studies) with 21,365 cases and 29,280 controls met the inclusion criteria. 9-23 A total of 14 studies were performed in Asians, 11 studies were performed in Caucasians, and four studies in Iranian-Azeri. Controls of 19 studies were population-based controls and 10 studies were hospital-based controls.…”

“…The pooled results based on 17 included studies (including 13,876 cases and 20,212 controls) indicated that rs4245739 was significantly related to a reduced risk of cancer in allelic contrast (B vs. A: OR = 0.83, 95% CI = 0.75-0.92, P = 0.000) and dominant model (AB + BB vs. AA: OR = 0.81, 95% CI = 0.71-0.91, P = 0.001). [9][10][11][17][18][19][20][21][22][23] Then, in the stratification analysis by cancer type, we observed that rs4245739 polymorphism was significantly related to a decreased risk of breast cancer in a recessive model (BB vs. AA + AB: OR = 0.75, 95% CI = 0.59-0.95, P =0.019, Figure 2). In addition, in the stratification analysis by ethnicity, we observed that rs4245739 polymorphism was significantly related to a decreased cancer risk for Asians in allelic contrast (B vs. A: OR = 0.56, 95% CI = 0.48-0.66, P = 0.000, Figure 3), dominant model (BB + AB vs. AA: OR = 0.54, 95% CI = 0.46-0.64, P = 0.000) and recessive model (BB vs. AA + AB: OR = 0.56, 95% CI = 0.32-0.98, P = 0.041).…”

“…Hashemi et al 9 reported that rs4245739 and rs11801299 had no significant correlation with breast cancer (BC) risk, while rs1380576 might be a protective factor for BC risk. Zhao et al 10 reported that rs4245739 might play a protective role in colorectal cancer risk. Mohammad Khanlou et al 11 reported that rs4245739 had no significant effect in thyroid cancer.…”

Contributions of NFKB1 ‐94insertion/deletion ATTG polymorphism to the susceptibility of gastrointestinal cancers: A meta‐analysis

“… 8 , 9 , 10 , 11 Single nucleotide polymorphisms (SNPs), the most common and effective variant type, are significantly associated with cancer susceptibility. 12 , 13 , 14 …”

“…[8][9][10][11] Single nucleotide polymorphisms (SNPs), the most common and effective variant type, are significantly associated with cancer susceptibility. [12][13][14] NF-κB, short for nuclear factor kappa B, is a pluripotent and critical dimer transcription factor. NF-κB orchestrates multiple physiological and pathological processes, particularly in cell survival, differentiation, inflammation and carcinogenesis.…”